Enzalutamide in Metastatic Castration-Resistant Prostate Cancer, Real-World Data.
| Autor: | Bahceci, Aykut, Sedef, Ali Murat, Aktas, Gokmen, Olgun, Polat, Cinkir, Havva Yesil, Taskaynatan, Halil, Kus, Tulay |
|---|---|
| Předmět: |
DRUG efficacy
RESEARCH ANTIANDROGENS ANALYSIS of variance METASTASIS RETROSPECTIVE studies ACQUISITION of data CASTRATION-resistant prostate cancer TREATMENT effectiveness CELLULAR signal transduction T-test (Statistics) MEDICAL records DESCRIPTIVE statistics KAPLAN-Meier estimator CHI-squared test PROGRESSION-free survival DATA analysis software DRUG resistance in cancer cells OVERALL survival PATIENT safety |
| Zdroj: | Eurasian Journal of Medical Investigation; 2023, Vol. 7 Issue 1, p1-7, 7p |
| Abstrakt: | Objectives: Androgen deprivation therapy (ADT) is used alone or in combination with docetaxel or androgen inhibitors in the initial treatment of metastatic PC (mPC). Enzalutamide is an androgen receptor inhibitor that is used orally and plays a role in different steps of the androgen receptor (AR) signal pathway. The aim of this study is to determine the real life data of patients using enzalutamide for metastatic PC. Methods: 118 patients from totally 6 centers using enzalutamide treatment were included in this retrospective analysis. Clinical information of patients were recorded from patient files or automation records. Results: Median OS was 71 months and median PFS was 5 months (4,1-5,9 months). There was no association of Gleason score with OS and PFS (p=0.5 and p=0.4, respectively). Although those who were metastatic at the time of diagnosis lived longer than those who developed metastases later, the difference was not statistically significant (p=0.9). Likewise, there was no relationship between the time of metastasis development and PFS (p=0.2). There was no difference in OS and PFS between patients with visceral metastasis and those without (p=0.3, p=0.5, respectively). Conclusion: Enzalutamide is an effective and safe agent in accordance with the literature in the patient group included in this study, although some patients may have an unresponsiveness to enzalutamide or develop progression under the enzalutamide treatment. More studies are needed to understand which patient group can benefit more from enzalutamide. [ABSTRACT FROM AUTHOR] |
| Databáze: | Complementary Index |
| Externí odkaz: |
|